Citation Impact
Citing Papers
Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome
2015 StandoutNobel
Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
2008
Messenger RNA-Based Vaccines Against Infectious Diseases
2020 StandoutNobel
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
2010 Standout
Mechanism of action of licensed vaccine adjuvants
2009
Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination
2015 StandoutNobel
Immune modulation by bacterial outer membrane vesicles
2015
Extracellular Vesicle RNA: A Universal Mediator of Microbial Communication?
2018 StandoutNobel
Correlates of vaccine protection from influenza and its complications
2012
Influenza vaccine: The challenge of antigenic drift
2007
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally
2009
Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
2014 StandoutNobel
Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement
2011
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo
2011 StandoutNobel
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site
2017 StandoutNobel
Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients
2010
Factors that may impact on immunosenescence: an appraisal
2010
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
2009
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
2010 StandoutNobel
Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions
2015 Standout
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications
2007
Influenza vaccine immunology
2010
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
2010
Microneedles for drug and vaccine delivery
2012 Standout
Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens
2008
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
2009
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses
2009
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
2009
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
2016
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Chitosan—A versatile semi-synthetic polymer in biomedical applications
2011 Standout
Strong serological responses and HIV RNA increase following AS 03‐adjuvanted pandemic immunization in HIV ‐infected patients
2011
Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines.
2013 StandoutNobel
Vaccine innovations for emerging infectious diseases—a symposium report
2019 StandoutNobel
Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults
2007
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
2010
Proteomic Analysis and Immunogenicity of Mannheimia haemolytica Vesicles
2012
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
2007
Works of Daniela Toneatto being referenced
A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
2013
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
2011
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
2013
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy
2003
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
2006